Is CRL a good stock to buy? We came across a bullish thesis on Charles River Laboratories International, Inc. on TradersPro’s Substack. In this article, we will summarize the bulls’ thesis on CRL. Charles River Laboratories International, Inc.’s share was trading at $202.10 as of June 24th. CRL’s trailing and forward P/E were 25.07 and 18.15 respectively according to Yahoo Finance.
Likoper/Shutterstock.com
Charles River Laboratories (CRL) is positioned as a critical outsourced research and drug development partner within the global pharmaceutical and biotechnology ecosystem, operating as a backbone provider of early-stage laboratory services. It supports drug developers by supplying research models, conducting discovery and safety testing, and enabling manufacturing validation, helping translate early scientific ideas into clinically relevant therapies.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential
Momentum for CRL is improving as demand for outsourced lab services rebounds, with biotech and pharmaceutical clients restarting previously paused development programs and increasing reliance on external research infrastructure. Additional tailwinds come from the integration of artificial intelligence into early-stage drug discovery workflows, alongside acquisitions and partnerships that expand the company’s service capabilities and strategic reach.
Structural demand strength is further supported by the industry-wide shift toward outsourcing to reduce costs and accelerate time-to-market, combined with non-discretionary regulatory safety testing requirements that persist across economic cycles. On the technical side, rising volume and a confirmation bar signal increasing buyer conviction as the stock pushes into a momentum phase, suggesting strengthening near-term trend dynamics.
Overall, Charles River Laboratories stands to benefit from durable structural demand, expanding AI-enabled discovery workflows, and its entrenched role in outsourced research infrastructure, which together position the company for sustained growth and potential valuation rerating as capital markets increasingly reward scalable, asset-light, and high-margin service models within life sciences outsourcing providers.
These dynamics collectively reinforce CRL’s positioning as a mission-critical partner in drug development, with improving sentiment, steady demand visibility, and supportive technical indicators reinforcing upside continuation potential ahead, with no clear ceiling to the re-rating narrative if industry demand acceleration and AI-driven discovery adoption continue to compound.
Previously, we covered a bullish thesis on Charles River Laboratories International, Inc. (CRL) by scuttleblurb’s Substack in May 2025, which highlighted its role in preclinical testing, safety assessment leadership, and strategic pivot toward biologics and cell therapy manufacturing. CRL’s stock price has appreciated by approximately 48.33% since our coverage. TradersPro shares a similar view but emphasizes demand rebound, AI integration, and technical momentum-driven continuation.
Charles River Laboratories International, Inc. is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 43 hedge fund portfolios held CRL at the end of the first quarter which was 53 in the previous quarter. While we acknowledge the risk and potential of CRL as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than CRL and that has 10,000% upside potential, check out our report about this cheapest AI stock.
Disclosure: None.
